npj Precision Oncology (Feb 2021)
Rare deleterious germline variants and risk of lung cancer
- Yanhong Liu,
- Jun Xia,
- James McKay,
- Spiridon Tsavachidis,
- Xiangjun Xiao,
- Margaret R. Spitz,
- Chao Cheng,
- Jinyoung Byun,
- Wei Hong,
- Yafang Li,
- Dakai Zhu,
- Zhuoyi Song,
- Susan M. Rosenberg,
- Michael E. Scheurer,
- Farrah Kheradmand,
- Claudio W. Pikielny,
- Christine M. Lusk,
- Ann G. Schwartz,
- Ignacio I. Wistuba,
- Michael H. Cho,
- Edwin K. Silverman,
- Joan Bailey-Wilson,
- Susan M. Pinney,
- Marshall Anderson,
- Elena Kupert,
- Colette Gaba,
- Diptasri Mandal,
- Ming You,
- Mariza de Andrade,
- Ping Yang,
- Triantafillos Liloglou,
- Michael P. A. Davies,
- Jolanta Lissowska,
- Beata Swiatkowska,
- David Zaridze,
- Anush Mukeria,
- Vladimir Janout,
- Ivana Holcatova,
- Dana Mates,
- Jelena Stojsic,
- Ghislaine Scelo,
- Paul Brennan,
- Geoffrey Liu,
- John K. Field,
- Rayjean J. Hung,
- David C. Christiani,
- Christopher I. Amos
Affiliations
- Yanhong Liu
- Dan L. Duncan Comprehensive Cancer Center, Department of Medicine, Baylor College of Medicine
- Jun Xia
- Institute for Clinical and Translational Research, Baylor College of Medicine
- James McKay
- International Agency for Research on Cancer
- Spiridon Tsavachidis
- Dan L. Duncan Comprehensive Cancer Center, Department of Medicine, Baylor College of Medicine
- Xiangjun Xiao
- Institute for Clinical and Translational Research, Baylor College of Medicine
- Margaret R. Spitz
- Dan L. Duncan Comprehensive Cancer Center, Department of Medicine, Baylor College of Medicine
- Chao Cheng
- Dan L. Duncan Comprehensive Cancer Center, Department of Medicine, Baylor College of Medicine
- Jinyoung Byun
- Dan L. Duncan Comprehensive Cancer Center, Department of Medicine, Baylor College of Medicine
- Wei Hong
- Institute for Clinical and Translational Research, Baylor College of Medicine
- Yafang Li
- Dan L. Duncan Comprehensive Cancer Center, Department of Medicine, Baylor College of Medicine
- Dakai Zhu
- Institute for Clinical and Translational Research, Baylor College of Medicine
- Zhuoyi Song
- Institute for Clinical and Translational Research, Baylor College of Medicine
- Susan M. Rosenberg
- Department of Molecular and Human Genetics, Baylor College of Medicine
- Michael E. Scheurer
- Dan L. Duncan Comprehensive Cancer Center, Department of Medicine, Baylor College of Medicine
- Farrah Kheradmand
- Dan L. Duncan Comprehensive Cancer Center, Department of Medicine, Baylor College of Medicine
- Claudio W. Pikielny
- Department of Biomedical Data Science, Geisel School of Medicine, Dartmouth College
- Christine M. Lusk
- Karmanos Cancer Institute, Wayne State University
- Ann G. Schwartz
- Karmanos Cancer Institute, Wayne State University
- Ignacio I. Wistuba
- Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center
- Michael H. Cho
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School
- Edwin K. Silverman
- Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School
- Joan Bailey-Wilson
- National Human Genome Research Institute
- Susan M. Pinney
- University of Cincinnati College of Medicine
- Marshall Anderson
- University of Cincinnati College of Medicine
- Elena Kupert
- University of Cincinnati College of Medicine
- Colette Gaba
- The University of Toledo College of Medicine
- Diptasri Mandal
- Louisiana State University Health Sciences Center
- Ming You
- Medical College of Wisconsin
- Mariza de Andrade
- Mayo Clinic College of Medicine
- Ping Yang
- Mayo Clinic College of Medicine
- Triantafillos Liloglou
- Roy Castle Lung Cancer Research Programme, The University of Liverpool, Department of Molecular and Clinical Cancer Medicine
- Michael P. A. Davies
- Roy Castle Lung Cancer Research Programme, The University of Liverpool, Department of Molecular and Clinical Cancer Medicine
- Jolanta Lissowska
- M. Sklodowska-Curie National Research Institute of Oncology
- Beata Swiatkowska
- Nofer Institute of Occupational Medicine, Department of Environmental Epidemiology
- David Zaridze
- Russian N.N. Blokhin Cancer Research Centre
- Anush Mukeria
- Russian N.N. Blokhin Cancer Research Centre
- Vladimir Janout
- Faculty of Health Sciences, Palacky University
- Ivana Holcatova
- Institute of Public Health and Preventive Medicine, Charles University, 2nd Faculty of Medicine
- Dana Mates
- National Institute of Public Health
- Jelena Stojsic
- Department of Thoracopulmonary Pathology, Service of Pathology, Clinical Center of Serbia
- Ghislaine Scelo
- International Agency for Research on Cancer
- Paul Brennan
- International Agency for Research on Cancer
- Geoffrey Liu
- Princess Margaret Cancer Center
- John K. Field
- Roy Castle Lung Cancer Research Programme, The University of Liverpool, Department of Molecular and Clinical Cancer Medicine
- Rayjean J. Hung
- Lunenfeld-Tanenbaum Research Institute, Sinai Health System
- David C. Christiani
- Harvard University T. H. Chan School of Public Health
- Christopher I. Amos
- Dan L. Duncan Comprehensive Cancer Center, Department of Medicine, Baylor College of Medicine
- DOI
- https://doi.org/10.1038/s41698-021-00146-7
- Journal volume & issue
-
Vol. 5,
no. 1
pp. 1 – 12
Abstract
Abstract Recent studies suggest that rare variants exhibit stronger effect sizes and might play a crucial role in the etiology of lung cancers (LC). Whole exome plus targeted sequencing of germline DNA was performed on 1045 LC cases and 885 controls in the discovery set. To unveil the inherited causal variants, we focused on rare and predicted deleterious variants and small indels enriched in cases or controls. Promising candidates were further validated in a series of 26,803 LCs and 555,107 controls. During discovery, we identified 25 rare deleterious variants associated with LC susceptibility, including 13 reported in ClinVar. Of the five validated candidates, we discovered two pathogenic variants in known LC susceptibility loci, ATM p.V2716A (Odds Ratio [OR] 19.55, 95%CI 5.04–75.6) and MPZL2 p.I24M frameshift deletion (OR 3.88, 95%CI 1.71–8.8); and three in novel LC susceptibility genes, POMC c.*28delT at 3′ UTR (OR 4.33, 95%CI 2.03–9.24), STAU2 p.N364M frameshift deletion (OR 4.48, 95%CI 1.73–11.55), and MLNR p.Q334V frameshift deletion (OR 2.69, 95%CI 1.33–5.43). The potential cancer-promoting role of selected candidate genes and variants was further supported by endogenous DNA damage assays. Our analyses led to the identification of new rare deleterious variants with LC susceptibility. However, in-depth mechanistic studies are still needed to evaluate the pathogenic effects of these specific alleles.